鉴定了一种针对阿尔茨海默氏病风险的e4特异性血基分子途径
Qiushan Tao1,2, Chao Zhang3, Gustavo Mercier4
1Department of Pharmacology, Physiology & Biophysics Boston University School of Medicine Boston Massachusetts USA.
Alzheimer's & dementia (Amsterdam, Netherlands)
|October 19, 2023
概括
一个涉及C-反应蛋白 (CRP),C3和CFH的阿尔茨海默氏病 (AD) 途径在APOE ε4载体中被特定. 准这些蛋白质可能为该群体的AD风险提供治疗效益.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
背景情况:
- 将阿波利波蛋白E (APOE) ε4与阿尔茨海默病 (AD) 风险联系在一起的精确分子机制仍然不完全理解.
- 识别APOE ε4特定途径对于开发向的AD疗法至关重要.
研究的目的:
- 阐明与阿尔茨海默病风险相关的APOE ε4特异性分子通路.
- 通过APOE基因型分层的研究血蛋白模块,AD诊断和AD生物标志物之间的关系.
主要方法:
- 权重基因共同表达网络分析 (WGCNA) 用于分析阿尔茨海默氏病神经成像倡议 (ADNI) 队列中的血蛋白模块.
- 多变量回归分析检查了蛋白质模块,AD诊断,CSF酸化 (p-tau) 和大脑葡萄糖代谢之间的关联,按APOE基因型分层.
主要成果:
- 一个特定的蛋白质模块 (绿色模块) 与APOE ε4同胞体的AD诊断有显著的关联.
- C-反应蛋白 (CRP),补充C3和补充因子H (CFH) 显示了与CSF p-tau,认知障碍和大脑葡萄糖低代谢的剂量依赖关系,仅在APOE ε4同胞体中.
- 这些发现在独立的队列中得到了验证,加强了它们的临床相关性.
结论:
- 该研究确定了一种新的APOE ε4特异性炎症途径,涉及CRP,C3和CFH,作为AD风险的关键因素.
- 准这种CRP-C3-CFH通路为缓解APOE ε4载体AD发病和进展提供了潜在的治疗策略.
关键词:
阿尔茨海默氏症的疾病是阿尔茨海默氏症.在C-反应性蛋白中,C-反应性蛋白是最重要的.与年龄相关的黄斑变性.粉样ββ的化物.亚脂蛋白 E 是一种非脂蛋白 E.大脑脊髓液酸化的.认知障碍是一种认知障碍.补充 C3 补充 C3 补充补充因子 H 是 H 的补充因子.低代谢收指数 (hypometabolic convergence index) 是指低代谢收指数 (hypometabolic convergence index) 是指低代谢收指数 (hypometabolic convergence index) 是指低代谢收指数 (hypometabolic convergence index) 是指低代谢收指数 (hypometabolic convergence index) 是指低代谢收指数 (hypometabolic convergence index) 是指低代谢收指数 (hypometabolic convergence index) 是指低代谢收指数 (hypometabolic convergence index) 是指低代谢收指数 (hypometabolic convergence index) 是指低代谢收指数 (hypometabolism).定子发射断层扫描 (PET).更多相关视频
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.1K
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.9K
相关概念视频
01:26Alzheimer's Disease: Overview
500
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
500
01:22Alzheimer's Disease: Treatment
200
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
200